SciClone Receives U.S. Patent Allowance for Analogs of ZADAXIN(R)

Apr 17, 2001, 01:00 ET from SciClone Pharmaceuticals, Inc.

    SAN MATEO, Calif., April 17 /PRNewswire/ --
 SciClone Pharmaceuticals (Nasdaq:   SCLN) today announced it has received a
 Notice of Allowance for a U.S. patent covering newly described analogs of its
 lead drug ZADAXIN(R).  ZADAXIN is an immune system enhancer (ISE) with an
 amino acid sequence identical to the naturally occurring peptide, thymosin
 alpha 1, which plays a key role in the body's immune response to disease,
 including the differentiation and maturation of stem cells into "helper" and
 "killer" T-cells, as well as the identification and "tagging" of infected or
 cancerous cells for immune intervention.
     SciClone has built a portfolio of U.S. and international patents that are
 intended to protect the use of ZADAXIN for key indications including hepatitis
 C, hepatitis B and numerous cancers.  The new patent will give SciClone
 exclusive "composition of matter" rights to several families of ZADAXIN
 analogs the Company has determined could have proprietary therapeutic or
 biologic distinctions from its current "natural synthetic" formulation, such
 as length of circulation in the blood or alternative delivery techniques.
     "As we move into our phase 3 clinical programs for ZADAXIN in the U.S. and
 Europe, SciClone is expanding its intellectual property position to cover the
 most promising analogs of this important compound," said Donald R. Sellers,
 SciClone's President and Chief Executive Officer.  "This patent, along with
 our existing patent portfolio, adds to the protection of the substantial
 hepatitis and cancer franchise we are building with ZADAXIN.  It also provides
 us with future line extension opportunities should we decide to pursue a
 development program based on the possible incremental advantages offered by
 our proprietary analogs."
     ZADAXIN has been administered to over 3,000 subjects in over 70 clinical
 trials covering a broad range of diseases and to an estimated 7,000 patients
 commercially with virtually no serious drug related adverse events or
 toxicities.  ZADAXIN is approved for sale in 21 countries, principally for the
 treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for
 patients with weakened immune systems.  ZADAXIN is currently in a phase
 3 program in the U.S. in combination with Pegasys(R) (pegylated interferon
 alfa-2a) for the treatment of hepatitis C, in a phase 2 program in combination
 with lamivudine for the treatment of hepatitis B and in a phase 2 trial for
 the treatment of liver cancer.  In Europe, a pivotal phase 3 ZADAXIN hepatitis
 C program will complement the Company's U.S. hepatitis C program.  ZADAXIN is
 also in clinical trials in Japan and Australia.
     SciClone Pharmaceuticals is a global specialty pharmaceutical company that
 develops and commercializes novel medicines for the treatment of a broad range
 of the world's most serious diseases.  The Company is currently targeting
 malignant melanoma, liver cancer, hepatitis B, hepatitis C, HIV,
 drug-resistant tuberculosis and cystic fibrosis.  Press releases and corporate
 information from SciClone Pharmaceuticals are available on the Internet at
 www.sciclone.com or by calling the Company's Investor Relations Department at
 800-724-2566.  SciClone's Common Stock is listed on The Nasdaq National
 Market(R) under the symbol SCLN.
 
     The information in this press release includes certain forward-looking
 statements concerning the Company's current expectations regarding future
 events.  These statements include those regarding the ongoing and prospective
 development and commercialization of ZADAXIN for hepatitis and cancer in the
 U.S., the timing of enrollment and potential success of the Company's ZADAXIN
 clinical trials in hepatitis C, liver cancer, malignant melanoma and
 drug-resistant tuberculosis.  The actual outcomes may differ from those
 expected due to risks including the inability to obtain regulatory approvals,
 the failure of the Company's products to show efficacy in clinical trials or
 the failure of the Company's partners to carry out commitments to the Company,
 and possible entry of competition based on the competitive approvals for
 indication that are not covered by "use" patents, as well as other risks and
 uncertainties including those reflected in the Company's filings with the
 Securities and Exchange Commission, particularly its Annual Report on
 Form 10-K for the year ended December 31, 2000.
 
 

SOURCE SciClone Pharmaceuticals, Inc.
    SAN MATEO, Calif., April 17 /PRNewswire/ --
 SciClone Pharmaceuticals (Nasdaq:   SCLN) today announced it has received a
 Notice of Allowance for a U.S. patent covering newly described analogs of its
 lead drug ZADAXIN(R).  ZADAXIN is an immune system enhancer (ISE) with an
 amino acid sequence identical to the naturally occurring peptide, thymosin
 alpha 1, which plays a key role in the body's immune response to disease,
 including the differentiation and maturation of stem cells into "helper" and
 "killer" T-cells, as well as the identification and "tagging" of infected or
 cancerous cells for immune intervention.
     SciClone has built a portfolio of U.S. and international patents that are
 intended to protect the use of ZADAXIN for key indications including hepatitis
 C, hepatitis B and numerous cancers.  The new patent will give SciClone
 exclusive "composition of matter" rights to several families of ZADAXIN
 analogs the Company has determined could have proprietary therapeutic or
 biologic distinctions from its current "natural synthetic" formulation, such
 as length of circulation in the blood or alternative delivery techniques.
     "As we move into our phase 3 clinical programs for ZADAXIN in the U.S. and
 Europe, SciClone is expanding its intellectual property position to cover the
 most promising analogs of this important compound," said Donald R. Sellers,
 SciClone's President and Chief Executive Officer.  "This patent, along with
 our existing patent portfolio, adds to the protection of the substantial
 hepatitis and cancer franchise we are building with ZADAXIN.  It also provides
 us with future line extension opportunities should we decide to pursue a
 development program based on the possible incremental advantages offered by
 our proprietary analogs."
     ZADAXIN has been administered to over 3,000 subjects in over 70 clinical
 trials covering a broad range of diseases and to an estimated 7,000 patients
 commercially with virtually no serious drug related adverse events or
 toxicities.  ZADAXIN is approved for sale in 21 countries, principally for the
 treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for
 patients with weakened immune systems.  ZADAXIN is currently in a phase
 3 program in the U.S. in combination with Pegasys(R) (pegylated interferon
 alfa-2a) for the treatment of hepatitis C, in a phase 2 program in combination
 with lamivudine for the treatment of hepatitis B and in a phase 2 trial for
 the treatment of liver cancer.  In Europe, a pivotal phase 3 ZADAXIN hepatitis
 C program will complement the Company's U.S. hepatitis C program.  ZADAXIN is
 also in clinical trials in Japan and Australia.
     SciClone Pharmaceuticals is a global specialty pharmaceutical company that
 develops and commercializes novel medicines for the treatment of a broad range
 of the world's most serious diseases.  The Company is currently targeting
 malignant melanoma, liver cancer, hepatitis B, hepatitis C, HIV,
 drug-resistant tuberculosis and cystic fibrosis.  Press releases and corporate
 information from SciClone Pharmaceuticals are available on the Internet at
 www.sciclone.com or by calling the Company's Investor Relations Department at
 800-724-2566.  SciClone's Common Stock is listed on The Nasdaq National
 Market(R) under the symbol SCLN.
 
     The information in this press release includes certain forward-looking
 statements concerning the Company's current expectations regarding future
 events.  These statements include those regarding the ongoing and prospective
 development and commercialization of ZADAXIN for hepatitis and cancer in the
 U.S., the timing of enrollment and potential success of the Company's ZADAXIN
 clinical trials in hepatitis C, liver cancer, malignant melanoma and
 drug-resistant tuberculosis.  The actual outcomes may differ from those
 expected due to risks including the inability to obtain regulatory approvals,
 the failure of the Company's products to show efficacy in clinical trials or
 the failure of the Company's partners to carry out commitments to the Company,
 and possible entry of competition based on the competitive approvals for
 indication that are not covered by "use" patents, as well as other risks and
 uncertainties including those reflected in the Company's filings with the
 Securities and Exchange Commission, particularly its Annual Report on
 Form 10-K for the year ended December 31, 2000.
 
 SOURCE  SciClone Pharmaceuticals, Inc.

RELATED LINKS

http://www.biospace.com/sciclone/